X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES PIRAMAL ENTERPRISES ALKEM LABORATORIES/
PIRAMAL ENTERPRISES
 
P/E (TTM) x - 11.1 - View Chart
P/BV x 6.9 1.9 363.5% View Chart
Dividend Yield % 0.6 0.9 73.1%  

Financials

 ALKEM LABORATORIES   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
PIRAMAL ENTERPRISES
Mar-18
ALKEM LABORATORIES/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,5893,083 51.5%   
Low Rs1,2321,902 64.8%   
Sales per share (Unadj.) Rs417.5589.7 70.8%  
Earnings per share (Unadj.) Rs56.3284.0 19.8%  
Cash flow per share (Unadj.) Rs64.7310.5 20.8%  
Dividends per share (Unadj.) Rs12.7025.00 50.8%  
Dividend yield (eoy) %0.91.0 89.8%  
Book value per share (Unadj.) Rs292.91,467.0 20.0%  
Shares outstanding (eoy) m119.57180.27 66.3%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.44.2 79.9%   
Avg P/E ratio x25.18.8 285.5%  
P/CF ratio (eoy) x21.88.0 271.6%  
Price / Book Value ratio x4.81.7 283.4%  
Dividend payout %22.68.8 256.3%   
Avg Mkt Cap Rs m168,653449,332 37.5%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m9,17119,881 46.1%   
Avg. sales/employee Rs ThNM15,535.6-  
Avg. wages/employee Rs ThNM2,905.4-  
Avg. net profit/employee Rs ThNM7,482.5-  
INCOME DATA
Net Sales Rs m49,915106,310 47.0%  
Other income Rs m1,6452,595 63.4%   
Total revenues Rs m51,561108,906 47.3%   
Gross profit Rs m8,48251,599 16.4%  
Depreciation Rs m1,0064,773 21.1%   
Interest Rs m67129,783 2.3%   
Profit before tax Rs m8,45119,638 43.0%   
Minority Interest Rs m-1142,801 -4.1%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,606-28,764 -5.6%   
Profit after tax Rs m6,73151,203 13.1%  
Gross profit margin %17.048.5 35.0%  
Effective tax rate %19.0-146.5 -13.0%   
Net profit margin %13.548.2 28.0%  
BALANCE SHEET DATA
Current assets Rs m27,062118,154 22.9%   
Current liabilities Rs m15,324462,260 3.3%   
Net working cap to sales %23.5-323.7 -7.3%  
Current ratio x1.80.3 690.9%  
Inventory Days Days6727 250.2%  
Debtors Days Days4147 88.7%  
Net fixed assets Rs m12,610113,727 11.1%   
Share capital Rs m239361 66.3%   
"Free" reserves Rs m34,490264,093 13.1%   
Net worth Rs m35,027264,454 13.2%   
Long term debt Rs m1,212242,206 0.5%   
Total assets Rs m54,387726,834 7.5%  
Interest coverage x13.61.7 819.7%   
Debt to equity ratio x00.9 3.8%  
Sales to assets ratio x0.90.1 627.5%   
Return on assets %13.611.1 122.1%  
Return on equity %19.219.4 99.3%  
Return on capital %24.910.3 241.2%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56315,110 43.4%   
Fx outflow Rs m3,0124,298 70.1%   
Net fx Rs m3,55210,813 32.8%   
CASH FLOW
From Operations Rs m7,259-159,666 -4.5%  
From Investments Rs m1,864-17,677 -10.5%  
From Financial Activity Rs m-9,273186,503 -5.0%  
Net Cashflow Rs m-1509,364 -1.6%  

Share Holding

Indian Promoters % 66.9 52.9 126.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 4.0 827.5%  
FIIs % 0.0 26.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 16.5 -  
Shareholders   68,381 93,274 73.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   WYETH LTD  PFIZER  NATCO PHARMA  SUN PHARMA  SANOFI INDIA  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 18, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - PLETHICO PHARMA COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS